Explainable AI in Clinical Trials
Clinical trial AI should do more than detect patterns. It must help teams understand, challenge, and document the rationale behind risk signals. Cyntegrity’s latest research reference explores how explainable mathematical discovery can support the next generation of RBQM innovation.
RBQM Explained: Why 100% SDV Falls Short in Clinical Trials
An educational excerpt from MyRBQM Essentials White Belt explaining why traditional monitoring and 100% Source Data Verification are no longer enough for modern clinical trial oversight.
Protocol Complexity and RBQM in Clinical Trials
New research shows protocol complexity continues to increase. Learn why Risk-Based Quality Management and AI-supported oversight are becoming essential.
AI Literacy in Clinical Trials Under ICH E6(R3)
AI-supported workflows in clinical trials increasingly fall within GCP, computerized system, data integrity, and AI governance expectations. Sponsors and CROs need teams that understand oversight, validation, accountability, and responsible AI use.
FDA Warning Letter Highlights AI Oversight Risks in Clinical Trials
FDA’s warning letter signals a shift: AI use without oversight is a compliance risk. What clinical trial teams must understand to stay inspection-ready.
Risk-Based Quality Management in Medical Devices: ISO 14155 vs ICH E6(R3)
Medical device investigations are now assessed like RBQM trials. Learn how ISO 14155 and ICH E6(R3) align and download the practical translation guide.
From spreadsheets to Digital RACT | ICH E6(R3) compliance
Learn why spreadsheet-based RACT falls short of ICH E6(R3) and how Digital RACT in the MyRBQM Portal delivers traceable, inspection-ready risk governance.
From EMA Findings to ICH E6(R3): QbD and RBQM in Practice
How EMA inspection findings translate into ICH E6(R3) expectations, and why Quality by Design and RBQM must operate together in clinical trials.
Risk-based quality management in 2026
Risk-based quality management in 2026: how ICH E6(R3) defines RBQM, where practice diverges, and what regulators now expect in clinical trials.
FDA AI Guidance 2025 Interactive Visualizer
Explore how FDA’s 2025 AI guidance shapes lifecycle oversight for AI-enabled medical software through interactive regulatory scenarios.
